Navigation Links
Nanosyn, Inc. and PCAS Announce the Signing of a Joint-Venture Agreement to Operate PCAS-NANOSYN, LLC

LONGJUMEAU, PARIS and MENLO PARK, Calif., Aug. 12 /PRNewswire/ -- PCAS, a worldwide leader in commercial scale pharmaceutical synthesis and fine and specialty chemical manufacturing, and Nanosyn, a leading US based pharmaceutical contract research provider of preclinical chemistry and biology services, announce the signing of a joint-venture agreement to operate PCAS-NANOSYN, LLC, a Good Manufacturing Practice (cGMP) kilolab in Santa Rosa, Northern California.

The newly created company, PCAS-NANOSYN, LLC, will enable PCAS and Nanosyn to satisfy a broader range of customer needs in the pharmaceutical and biotech marketplaces by offering fully integrated custom chemical services from discovery to commercialization.

"The formation of this JV with such a reputable partner as we have found in Nanosyn allows us to place critical preclinical and clinical trial API synthetic capabilities nearer to our clients in the US," said Christian Moretti, Chairman of PCAS, "It is an ideal next step in our strategy to continue growing our customer base in North America and builds on the success of our PCAS America marketing office in New Jersey."

The joint venture operation will provide services out of an FDA inspected facility in Santa Rosa, California, housing six (GMP) suites, two of which are certified as Class 10,000 clean rooms. PCAS-NANOSYN, LLC customers will further benefit from the significant chemical and analytical resources within the parent companies, and the ability to seamlessly transfer projects for larger scale to PCAS' network of four FDA inspected pilot and commercial scale plants in Europe.

"We are excited to offer this suite of cGMP solutions as a result of this partnership. For our clients, this is a natural extension of Nanosyn's highly successful discovery services into process development, scale-up, and supply of preclinical and cGMP clinical trial quantities of APIs," said Nikolai Sepetov, President and CEO of Nanosyn, Inc. "Ensuring quality, start to finish, is fundamental to the success we share with our clients."

Currently, the PCAS-NANOSYN, LLC facility is fully operational and is founded on the assets of Seres Laboratories. Nanosyn acquired the physical assets of Seres in March of 2009 and retained its experienced staff in order to take advantage of its 30 year history as an FDA registered cGMP site. As part of PCAS-NANOSYN, LLC strategy to be the premier provider of high quality and cost efficient services for the pharmaceutical and biotechnology industries, the joint venture plans to expand the site by upgrading its existing R&D and analytical capabilities, while adding new, advanced capacities. Olga Issakova, Ph.D., Executive Vice President of Nanosyn, Inc., will serve as CEO of the newly formed company.

About Nanosyn:

Nanosyn ( is a Contract Research Organization providing integrated drug discovery services, medicinal chemistry, made-to-order focused compound libraries, hit-to-lead optimization, assay development, screening and profiling services, process chemistry, and other innovative solutions to meet our partners' drug discovery needs. Founded in 1998, Nanosyn is privately held and self-funding. The company is headquartered in Menlo Park, California with sites in San Diego, California and Research Triangle Park, North Carolina.

About PCAS:

PCAS ( is a listed group on the Paris Stockmarket. A leading Fine Chemical company, PCAS operates eight chemical plants in Europe and North America and offers world-class services related to the process development and manufacturing of multi-step, complex organic chemicals from kilolab to multi-ton scale. PCAS provides services for the pharmaceutical, flavor and fragrance, cosmetic, and industrial market sectors.

Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Neurobiological Technologies Announces Termination of its License and Cooperation Agreement with Merz and Childrens Medical Center
2. Cryo-Cell Announces Strategic Partnership With S-Evans Biosciences, Inc.
3. WuXi PharmaTech Announces Second-Quarter 2009 Results
4. ValGenesis, Inc. Announces Integration of ValGenesis Solution with Microsoft SharePoint Server
5. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2009 Results
6. Advanced Life Sciences Announces Second Quarter 2009 Financial Results and Financial Outlook
7. Microfluidics International Corporation Announces Second Quarter 2009 Financial Results
8. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
9. American Oriental Bioengineering Announces Change in Independent Auditor
10. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
11. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
Post Your Comments:
(Date:11/27/2015)... /PRNewswire/--  Mallinckrodt plc (NYSE: MNK ), a ... closed the sale of its global contrast media and ... in a transaction valued at approximately $270 million. The ... total of approximately 1,000 employees spread across the globe, ... area. This entire workforce and the manufacturing ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
(Date:11/25/2015)... Francisco, CA (PRWEB) , ... November 25, 2015 ... ... microbial genomics company uBiome, were featured on AngelList early in their initial angel ... launching an AngelList syndicate for individuals looking to make early stage investments in ...
Breaking Biology Technology:
(Date:11/18/2015)... York , November 18, 2015 ... Research has published a new market report titled  Gesture ... Trends, and Forecast, 2015 - 2021. According to the report, ... 2014 and is anticipated to reach US$29.1 bn by ... 2021. North America dominated ...
(Date:11/17/2015)... -- Paris , qui s,est ... Paris , qui s,est tenu du 17 ... de l,innovation biométrique, a inventé le premier scanner couplé, ... la même surface de balayage. Jusqu,ici, deux scanners étaient ... empreintes digitales. Désormais, un seul scanner est en mesure ...
(Date:11/17/2015)... , Nov. 17, 2015 Pressure BioSciences, ... in the development and sale of broadly enabling, pressure ... life sciences industry, today announced it has received gross ... $5 million Private Placement (the "Offering"), increasing the total ...  One or more additional closings are expected in the ...
Breaking Biology News(10 mins):